home / stock / zyme / zyme quote
Last: | $6.43 |
---|---|
Change Percent: | 0.47% |
Open: | $6.39 |
Close: | $6.43 |
High: | $6.6 |
Low: | $6.23 |
Volume: | 1,007,698 |
Last Trade Date Time: | 12/15/2022 03:41:52 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.43 | $6.39 | $6.43 | $6.6 | $6.23 | 1,007,698 | 12-15-2022 |
$6.42 | $6.16 | $6.42 | $6.665 | $5.98 | 1,320,850 | 12-14-2022 |
$6.18 | $6.11 | $6.18 | $6.43 | $5.7601 | 735,473 | 12-13-2022 |
$6 | $6.58 | $6 | $6.68 | $5.95 | 1,350,646 | 12-12-2022 |
$6.71 | $7.24 | $6.71 | $8.22 | $6.56 | 1,331,614 | 12-09-2022 |
$7.08 | $7.48 | $7.08 | $7.63 | $7.045 | 603,505 | 12-08-2022 |
$7.4 | $7.12 | $7.4 | $7.55 | $6.6 | 1,463,499 | 12-07-2022 |
$7.03 | $7.64 | $7.03 | $8.07 | $6.94 | 2,240,498 | 12-06-2022 |
$7.62 | $7.56 | $7.62 | $7.73 | $7.32 | 892,131 | 12-05-2022 |
$7.58 | $7.73 | $7.58 | $7.78 | $7.17 | 1,059,851 | 12-02-2022 |
$7.73 | $7.77 | $7.73 | $8.0225 | $7.61 | 216,034 | 12-01-2022 |
$7.72 | $7.77 | $7.72 | $7.95 | $7.51 | 377,118 | 11-30-2022 |
$7.71 | $7.75 | $7.71 | $7.94 | $7.6 | 340,461 | 11-29-2022 |
$7.83 | $7.91 | $7.83 | $8.15 | $7.77 | 501,872 | 11-28-2022 |
$7.84 | $8.07 | $7.84 | $8.13 | $7.66 | 350,079 | 11-25-2022 |
$8.04 | $7.8 | $8.04 | $8.15 | $7.6894 | 551,520 | 11-24-2022 |
$8.04 | $7.8 | $8.04 | $8.15 | $7.6894 | 551,520 | 11-23-2022 |
$7.76 | $8.03 | $7.76 | $8.03 | $7.41 | 632,987 | 11-22-2022 |
$7.95 | $7.84 | $7.95 | $7.99 | $7.575 | 807,924 | 11-21-2022 |
$7.76 | $8.01 | $7.76 | $8.01 | $7.58 | 289,143 | 11-18-2022 |
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...